Nicole Rich, MD
Gastroenterology · Dallas, TXNPI 1033408182
Payments from drug & device makers
Across 50 payments — averaging $2100.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astrazeneca UK Limited$37K
- Bayer$32K
- Eisai Inc.$17K
- AstraZeneca$10K
- Madrigal Pharmaceuticals$5K
- Exelixis Inc.$2K
- plus $2K from 5 others
What the payments were for
- Consulting fees$15,08381%
- Speaking & faculty fees$1,77010%
- Travel & lodging$1431%
- Food & beverage$1,6359%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astrazeneca UK Limited | 2 | $37,120 |
| Bayer | 16 | $31,931 |
| Eisai Inc. | 9 | $17,326 |
| AstraZeneca | 8 | $9,743 |
| Madrigal Pharmaceuticals | 5 | $4,657 |
| Exelixis Inc. | 3 | $1,854 |
| Genentech USA, Inc. | 2 | $1,625 |
| Fujifilm Wako Diagnostics U.S.A. Corporation | 1 | $417 |
| Shockwave Medical, Inc | 2 | $162 |
| Novo Nordisk | 1 | $94 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $78 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- IMFINZI$6,419
- REZDIFFRA$4,373
- Cabometyx$1,770
- TECENTRIQ$1,625
- Wako HCC Biomarker(s) DCP and AFP-L3$417
- RESMETIROM$150
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$115
How this compares
$105,008 in reported general payments places this provider in the 90th percentile of 1,350 gastroenterology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Spironolactone | 22 | $195 |
| Furosemide | 13 | $22 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in Dallas
- John FordtranDallas$9.9M
- Parvez MantryDallas$6.4M
- Michael BrownDallas$5.5M
- Jacqueline O LearyDallas$1.4M
- Themistocles DassopoulosDallas$1.1M
- Moheb BoktorDallas$1M
- Lisa VanwagnerDallas$486K
- Rodney InfanteDallas$442K
- Eric LawitzSan Antonio$59.5M
- George DuvallTyler$17.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.